Compare Citius Pharmaceuticals Inc (CTXR) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while iShares 3 7 Year Treasury Bond ETF trades at $116.45. The key difference: Citius Pharmaceuticals Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| CTXR | IEI | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $120.72 |
52-Week Low | $0.48 | $116.16 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.46, up 0.18% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid recent dividends, including $0.38 per share in July 2026. News highlights focus on Treasury yield volatility amid inflation data and geopolitical tensions, influencing bond market sentiment.
Outlook is cautious due to bearish technicals and rising yield pressures. Opportunities include government backing and income from dividends, but risks involve Fed rate hike expectations and oil-driven inflation. Investors face volatility from macroeconomic shifts and bond market reactions to policy changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
